Edition:
United States

Marrone Bio Innovations Inc (MBII.OQ)

MBII.OQ on NASDAQ Stock Exchange Capital Market

1.75USD
4:00pm EDT
Change (% chg)

$0.04 (+2.34%)
Prev Close
$1.71
Open
$1.78
Day's High
$1.78
Day's Low
$1.65
Volume
14,368
Avg. Vol
8,690
52-wk High
$2.78
52-wk Low
$0.62

MBII.OQ

Chart for MBII.OQ

About

Marrone Bio Innovations, Inc. offers bio-based pest management and plant health products. The Company's bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate... (more)

Overall

Beta: 0.37
Market Cap(Mil.): $52.14
Shares Outstanding(Mil.): 30.49
Dividend: --
Yield (%): --

Financials

  MBII.OQ Industry Sector
P/E (TTM): -- 21.88 109.92
EPS (TTM): -1.26 -- --
ROI: -69.76 3.29 10.63
ROE: -- 6.16 13.79

BRIEF-Marrone Bio Innovations reports proposed public offering of common stock

* Marrone Bio Innovations, Inc announces proposed public offering of common stock Source text for Eikon: Further company coverage:

Apr 24 2017

BRIEF-Marrone Bio Innovations files for non-timely 10-K

* Marrone Bio Innovations Inc files for non-timely 10-K - SEC filing Source: (http://bit.ly/2nzVKYA) Further company coverage:

Apr 03 2017

BRIEF-Marrone Bio Innovations entered into invoice purchase agreement with LSQ Funding Group

* Marrone Bio Innovations Inc - entered into an invoice purchase agreement with Lsq Funding Group, L.C.

Mar 30 2017

BRIEF-Marrone Bio Innovations Q4 loss per share $ 0.32

* Marrone Bio Innovations reports fourth quarter and record full year 2016 results

Mar 29 2017

BRIEF-Marrone Bio Innovations to advance some novel bacteria, Evogene-identified related proteins into MBI'S bioinsecticide product development pipeline

* Evogene-Marrone bio innovations to advance some novel bacteria, Evogene-identified related proteins into MBI's bioinsecticide product development pipeline Source text for Eikon: Further company coverage:

Mar 28 2017

BRIEF-Marrone Bio Innovations' Majestene bionematicide approved in California

* Marrone Bio Innovations receives California approval for Majestene bionematicide Source text for Eikon: Further company coverage:

Nov 16 2016

BRIEF-Marrone Bio Innovations Q3 revenue $3.6 mln

* Qtrly total GAAP revenues for Q3 of 2016 up by 46.8% to $3.6 million

Nov 14 2016

More From Around the Web

Competitors

Earnings vs. Estimates